Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, Kitazono T, Ueno S, Taguchi R, Yoshihiro T, Doi Y, Arimizu K, Ohmura H, Kajitani T, Nio K, Nakano M, Oshima K, Tamura S, Shirakawa T, Shimokawa H, Uchino K, Hanamura F, Okumura Y, Komoda M, Isobe T, Ariyama H, Esaki T, Hashimoto K, Komune N, Matsuo M, Matsumoto K, Asai K, Yoshitake T, Yamamoto H, Oda Y, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: akashi k. BMC Cancer. 2023 Oct 31;23(1):1046. doi: 10.1186/s12885-023-11528-4. BMC Cancer. 2023. PMID: 37904096 Free PMC article.
RHAMM marks proliferative subpopulation of human colorectal cancer stem cells.
Nakano M, Taguchi R, Kikushige Y, Isobe T, Miyawaki K, Mizuno S, Tsuruta N, Hanamura F, Yamaguchi K, Yamauchi T, Ariyama H, Kusaba H, Nakamura M, Maeda T, Kuo CJ, Baba E, Akashi K. Nakano M, et al. Among authors: akashi k. Cancer Sci. 2023 Jul;114(7):2895-2906. doi: 10.1111/cas.15795. Epub 2023 Mar 31. Cancer Sci. 2023. PMID: 36945114 Free PMC article.
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: akashi k. Sci Rep. 2023 May 31;13(1):8815. doi: 10.1038/s41598-023-34962-7. Sci Rep. 2023. PMID: 37258608 Free PMC article.
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions.
Uehara K, Tanoue K, Yamaguchi K, Ohmura H, Ito M, Matsushita Y, Tsuchihashi K, Tamura S, Shimokawa H, Isobe T, Shibata Y, Ariyama H, Tanaka R, Kusaba H, Yamamoto H, Oda Y, Akashi K, Baba E. Uehara K, et al. Among authors: akashi k. Cancer Immunol Immunother. 2023 Nov;72(11):3543-3558. doi: 10.1007/s00262-023-03505-4. Epub 2023 Aug 7. Cancer Immunol Immunother. 2023. PMID: 37550428 Free PMC article.
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: akashi k. Sci Rep. 2024 Mar 4;14(1):5311. doi: 10.1038/s41598-024-55673-7. Sci Rep. 2024. PMID: 38438505 Free PMC article. No abstract available.
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Kato K, et al. Among authors: akashi k. Int J Hematol. 2023 Mar;117(3):409-420. doi: 10.1007/s12185-022-03494-7. Epub 2022 Nov 18. Int J Hematol. 2023. PMID: 36399286 Clinical Trial.
957 results